Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2006-08-22
2006-08-22
Whiteman, Brian (Department: 1635)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S325000, C435S366000
Reexamination Certificate
active
07094603
ABSTRACT:
Novel methods are disclosed for treating oncological disorders in an individual or animal using a superantigen expressed in tumor cells. A gene encoding a superantigen, such as an M-like protein of group A streptococci, can be introduced into a tumor cell in order to make the tumor cell more immunogenic in the host. Also contemplated are methods wherein a cell expresses a superantigen or superantigens, and immunogenic or immunostimulatory proteins, such as foreign MHC, cytokines, porcine-derived hyperacute rejection antigen,Mycobacterium-derived antigens, and the like. The subject invention also pertains to cells transformed with polynucleotides encoding a superantigen and foreign MHC antigen, cytokines, and other immunogenic or immunostimulatory proteins. Transformed cells according to the subject invention are then provided to an individual or animal in need of treatment for an oncological disorder. The immune response to tumor cells transformed according to the present invention inhibits in vivo tumor growth and results in subsequent tumor regression. The subject invention also pertains to cell lines transformed with genes encoding a superantigen and, optionally, a foreign Class II MHC antigen and/or a cytokine.
REFERENCES:
patent: 5736388 (1998-04-01), Chada et al.
patent: 2002/0193571 (2002-12-01), Carter et al.
patent: 0569678 (1993-11-01), None
patent: WO 93/24136 (1993-12-01), None
patent: WO 94/21808 (1994-09-01), None
patent: WO 95/00178 (1995-01-01), None
patent: WO 95/13092 (1995-05-01), None
patent: WO 96/29093 (1996-09-01), None
patent: WO 96/36366 (1996-11-01), None
Avery, A. C. et al. “Activation of T Cells by Superantigen in Class II-Negative Mice”J. Immunol., 1994, pp. 4855-4861, vol. 153.
Banchereau, J. et al., “Dendritic Cells and the Control of Immunity”Nature, 1998, pp. 245-252, vol. 392.
Barratt-Boyes, S. M. et al. “Studies in a Chimpanzee Model of Dendritic Cell-Based Cancer Vaccines”, Proceedings of the 87th, Annual Meeting of the American Association for Cancer, 1996, XP002039146 (abstract only).
Boyle, Michael D. P. et al. “Analysis of Genes Encoding Two Unique Type IIa Immunoglobulin G-Binding Proteins Expressed by a Single Group a Streptococcal Isolate”Infection and Immunology, 1994, pp. 1336-1347, vol. 62, No. 4.
Boyle, Michael D. P. et al. “Characterization of A Gene Coding for A Type IIo Bacterial IgG-Binding Protein”Molecular Immunology, 1995, pp. 669-678, vol. 32, No. 9.
Dellabona, Paolo et al. “Superantigens Interact With MHC Class II Molecules Outside of the Antigen Groove”Cell, 1990, pp. 1115-1121, vol. 62.
Dohlsten, M. et al. “Monoclonal Antibody-Targeted Superantigens: A Different Class of Anti-Tumor Agents”Proc. Natl. Acad. Sci. USA, 1991, pp. 9287-9291, vol. 88.
Dohlsten, M. et al. “Human Major Histocompatibility Complex Class II-Negative Colon Carcinoma Cells Present Staphylococcal Superantigens to Cytotoxic T Lymphocytes: Evidence for a Novel Enterotoxin Receptor”Eur. J. Immunol., 1991, pp. 1229-1233, vol. 21.
Dohlsten, M. et al. “Role of the Adhesion Molecule ICAM-1 (CD54) in Staphylococcal Enterotoxin-Mediated Cytotoxicity”Eur. J. Immunol., 1991, pp. 131-135, vol. 21.
Fleisher, B. et al. “T-Lymphocyte Stimulation by Microbial Superantigens”Chem. Immunol., 1992, pp. 36-64 vol. 55.
Fraser, James D. et al. “CD28 and T Cell Antigen Receptor Signal Transduction Coordinately Regulate Interleukin 2 Gene Expression In Response to Superantigen Stimulation”J. Ex. Med., 1992, pp. 1131-1134, vol. 175.
Gilboa, Eli et al. “Immunotherapy of Cancer With Dendritic-Cell-Based Vaccines”Cancer Immunol Immunother, 1998, pp. 82-87, vol. 46, No. 2.
Hartwig, Udo F. et al. “Mutations Affecting MHC Class II Binding of the Superantigen Streptococcal Erythrogenic Toxin A”International Immunology, 1993, pp. 869-875, vol. 5, No. 8.
Herman, Andrew et al. “Identification of the Staphylococcal Enterotoxin A Superantigen Binding Site in the β1 Domain of the Human Histocompatibility Antigen HLA-DR”,Proc. Natl. Acad. Sci. USA, 1991, pp. 9954-9958, vol. 88.
Hermann, Thomas et al. “Staphylococcal Enterotoxin-Dependent Lysis of MHC Class II Negative Target Cells by Cytolytic T Lymphocytes”,J. Immunol., 1991, pp. 2504-2512, vol. 146.
Hock, Randy A. et al. “Murine Neuroblastoma Vaccines Produced by Retroviral Transfer of MHC Class II Genes”,Cancer Gene Therapy, 1996, pp. 314-320, vol. 3, No. 5.
Johnson, Howard M. et al. “Superantigens in Human Disease”,Scientific American, 1992, pp. 92-111.
Karp, David R. et al. “The α1 Domain of the HLA-DR Molecule is Essential for High-Affinity Binding of the Toxic Shock Syndrome Toxin-1”,Nature, 1990, pp. 474-476, vol. 346.
Menard, S. et al. “Mycobacterium Tuberculosis Gene Transfer in Melanoma Cells Induces Antitumoral Immunity in Mice”Cancer Gene Therapy, 1995, p. 318, vol. 2, No. 4.
Mayordoma, J.I. et al. “Bone Marrow-Derived Dendritic Cells Pulsed With Synthetic Tumour Peptides Elicit Protective and Therapeutic Antitumour Immunity”,Nature Medicine, 1995, pp. 1297-1302, vol. 1, No. 12.
Mollick, Joseph A. et al. “Staphylococcal Exotoxin Activation of T Cells”,J. Immunology, 1991, pp. 463-468, vol. 146.
Panina-Bordignon, Paola et al. “Identification of HLA-DRα Chain Residues Critical for Binding of the Toxic Shock Syndrome Toxin Superantigen”,J. Exp. Med., 1992, pp. 1779-1784, vol. 176.
Rust, Chantal, J.J. et al. “Specific Recognition of Staphylococcal Enterotoxin A by Human T Cells Bearing Receptors With the V659 Region”,Nature, pp. 572-574, vol. 346.
Webb, Susan R. et al. “T-cell Activation by Superantigens”,Curr Opinion in Immun., 1994, pp. 467-475, vol. 6.
Tomai, M. et al. “Superantigenicity of Streptococcal M Protein”,J. Exp. Med., 1990, pp. 359-362, vol. 172.
Fleischer, B. et al. “Superantigens and Pseudosuperantigens of Gram-Positive Cocci”,Med. Microbiol. Immumol., 1995, pp. 1-8, vol. 184.
Degnan, B. et al. “Streptococcus pyogenesType 5 M Protein is an Antigen, Not a Superantigen, for Human T Cells”,Human Immunology, 1997, pp. 206-215, vol. 53.
Esaki, Y. et al. “Role of Human Major Histocompatibility Complex DQ Molecules in Superantigenicity ofStreptococcus-Derived Protein”,Infection and Immunity, 1994, p. 1228-1235, vol. 62, No. 4.
Anderson, W.F. “Human Gene Therapy”,Nature, 1998, pp. 25-30, vol. 392(Supp.).
Verma, I. M. et al. “Gene Therapy—Promises, Problems and Prospects”,Nature, 1997, pp. 239-242, vol. 389.
Gomez-Navarro, J. et al. “Gene Therapy for Cancer”,Eur. J. Cancer, 1999, pp. 867-885, vol. 35, No. 6.
Ngo, J. T. et al. “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox”,The Protein Folding Problem and Tertiary Structure Prediction, 1994, pp. 433 and 492-495, Merz (ed.) Birkhauser, Boston, MA.
Chiu, T-L. et al. “Optimizing Energy Potentials for Success in Protein Tertiary Structure Prediction”,Folding&Design, May 1998, pp. 223-228, vol. 3.
Orkin, S. H. et al. “Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy”, Dec. 1995, pp. 1-41.
Ross, G. et al. “Gene Therapy in the United States: A Five Year Status Report”,Human Gene Therapy, Sep. 1996, pp. 1781-1790, vol. 7.
Ostrand-Rosenberg, S. et al. “Tumor-Specific Immunity Can Be Enhanced by Transfection of Tumor Cells with Syngeneic MHC-Class-II Genes or Allogeneic MHC-Class-I Genes”,Int. J. Cancer, 1991, pp. 61-68, vol. 6.
Kalland, T. et al. “Targeting of Superantigens”,Cell Biophysics, 1993, pp. 147-164, vol. 22.
Coupar, B. E. H. et al. “A General Method for the Construction of Recombinant Vaccinia Viruses Expressing Multiple Foreign Genes”,Ge
Lawman Michael J. P.
Lawman Patricia
Edwards Angell Palmer & & Dodge LLP
Morphogenesis, Inc.
Whiteman Brian
LandOfFree
Materials and methods for treating oncological disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Materials and methods for treating oncological disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods for treating oncological disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3714671